PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues

Affiliations

• ¹ The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK.
• ² Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ³ Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
• ⁴ Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain.
• ⁵ Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
• ⁶ Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
• ⁷ Istituto Oncologico della Svizzera Italiana, Ente Ospedaliero Cantonale Bellinzona, Bellinzona, Switzerland.
• ⁸ Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
• ⁹ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ¹⁰ Tulane Cancer Center, Tulane University Medical School, New Orleans, LA, USA.
• ¹¹ South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.
• ¹² The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK. Electronic address: [email protected].